Immunogenic cell death

Show results for

Unknown (1929)
Genomics (188)
Transcriptomics (145)
Proteomics (33)
Other (8)
Clinical (5)
Metabolomics (3)
Methylation profiling (1)

Organisms

Homo sapiens (89)
Mus musculus (88)
Andropogon gerardi (17)
Bacteria (17)
Canis lupus familiaris (17)
Chromatiales bacterium OalgGamma1 (17)
Clavibacter nebraskensis NCPPB 2581 (17)
Cnidaria (17)
Ensifer adhaerens (17)
Fasciola (17)
Human alphaherpesvirus 1 strain 17 (17)
Human alphaherpesvirus 1 strain KOS (17)
Human betaherpesvirus 5 (17)
Human herpesvirus 2 strain 186 (17)
Mesocricetus auratus (17)
Miscanthus x giganteus (17)
Mus musculus (17)
Panicum virgatum (17)
Platyhelminthes (17)
Pseudomonas aeruginosa PA103 (17)
Rabies virus Nishigahara RCEH (17)
Rattus norvegicus (17)
Mycobacterium avium subsp. paratuberculosis (2)
Mycobacterium tuberculosis variant bovis BCG str. Pasteur 1173P2 (1)
Cryptococcus neoformans (1)
Rattus norvegicus (1)
Sus scrofa (1)
Equus caballus (1)
Mycobacterium tuberculosis (1)
cellular organisms (1)

Organisms

Mus musculus (72)
Homo sapiens (53)
Cancer sp. (1)
Equus caballus (1)
Mycobacterium tuberculosis (1)

Repository

ENA (173)
geo (132)
biostudies-arrayexpress (29)
pride (17)
EGA (10)
iProX (7)
MassIVE (6)
MetaboLights (3)
jPOST (1)

Tissue

Cell culture (6)
Epithelial cell (2)
Embryonic fibroblast (1)
Embryonic fibroblast cell line (1)
Epithelial melanocyte (1)
Fibroblast of lung (1)
Glioma cell (1)
Leukocyte (1)
Melanocyte (1)
Pancreas (1)
Papillary thyroid cancer cell line (1)
Prokaryotic cell (1)

Disease

Colorectal Neoplasms (4)
Melanoma (2)
Pancreatic cancer (2)
Cutaneous melanoma (1)
Colorectal cancer (1)
Disease free (1)
Skin melanoma (1)

Technology Type

Mass Spectrometry (17)
Shotgun proteomics (10)
Data-dependent acquisition (4)
Mass spectrometry assay (3)
ILLUMINA, Illumina HiSeq 2500 (1)
NMR spectroscopy assay (1)
Affinity purification coupled with mass spectrometry proteomics (1)
Bottom-up proteomics (1)
Data-independent acquisition (1)

Instrument Platform

Orbitrap Fusion Lumos (3)
Illumina HiSeq 2500 (2)
Liquid Chromatography MS - positive - reverse-phase (2)
Liquid Chromatography MS - negative - reverse-phase (2)
Illumina NovaSeq X (1)
Illumina NovaSeq 6000 (1)
Illumina HiSeq 2000 (1)
NextSeq 500 (1)
LTQ Orbitrap (1)
Orbitrap Fusion (1)
Q Exactive Plus (1)
TripleTOF 5600 (1)
Nuclear Magnetic Resonance (NMR) - (1)
Liquid Chromatography MS - alternating - reverse phase (1)
Liquid Chromatography MS - positive - hilic (1)
Liquid Chromatography MS - negative - reverse phase (1)

Publication Date

2026 (47)
2025 (41)
2024 (23)
2022 (15)
2023 (12)
2020 (10)
2014 (8)
2021 (6)
2018 (5)
2019 (5)
2016 (4)
2012 (3)
2009 (3)
2008 (3)
2013 (2)
2010 (2)
2017 (2)
2015 (1)

Metabolite Name

2-Octenoylcarnitine CAR(8:1) (1)

First Public Date

2026 (56)
2025 (39)
2024 (29)
2023 (12)
2022 (11)
2019 (8)
2020 (7)
2021 (5)
2018 (2)
2017 (2)
2014 (2)

Classification

bacteria (1)

Study status

Recruiting (3)
Completed (2)

Study type

Transcription profiling by array (19)
RNA-seq of coding RNA (7)
Interventional (5)
Proteomic profiling by array (2)
Unknown experiment type (1)

Release Date

2025 (393)
2022 (297)
2023 (285)
2024 (260)
2021 (180)
2020 (137)
2019 (91)
2026 (71)
2018 (62)
2017 (48)
2016 (41)
2015 (29)
2014 (28)
2012 (8)
2008 (7)
2010 (6)
2013 (5)
2009 (5)
2011 (2)
2007 (1)
2006 (1)
2005 (1)

Lab affiliation

The Institute of Cancer Research (2)
CNIO (1)
Cecad Research Center Cologne/Department of Translational Genomics, Cologne University medical center, Cologne, Germany (1)
Cell Death Investigation and Therapy (CDIT) Laboratory, Anatomy and Embryology Unit, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium (1)
Core Unit Proteomics, Berlin Institute of Health at Charite - Universitaetsmedizin Berlin and Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany (1)
Core Unit Proteomics, Berlin Institute of Health at Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany. (1)
Department of Chemistry, National University of Singapore (1)
Functional Proteomics, ICR (1)
Institute for Research in Biomedicine (IRB), Barcelona Institute of Science and Technology (BIST), Barcelona 08028, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona 08010, Spain (1)
Institute of Microbiology, Department of Microbial Proteomics, Center for Functional Genomics of Microbes, University of Greifswald, 17489 Greifswald, Germany (1)
Moffitt Cancer Center Tampa, FL, USA (1)
Molecular Proteomics Laboratory Institute for Molecular Medicine Heinrich-Heine-Universität Düsseldorf 40225 Düsseldorf Germany (1)
The Institute of Cancer Research, London (1)
Translational Control and Metabolism, German Cancer Research Center (DKFZ), Heidelberg, Germany (1)
Unit of Chemical Proteomics, Division of Chemistry I, Dept. of Medical Biochemistry and Biophysics (MBB), Karolnska Institutet, Biomedicum, Solna, Sweden (1)
università degli studi di Milano, medicina veterinaria, DIMEVET (1)

Location

France (3)
China (1)
Germany (1)
United States (1)
United Kingdom (1)
Switzerland (1)

Keyword

Tremelimumab (2)
Durvalumab (2)
Oncolytic Vaccinia Virus (1)
Tumor Cell Death (1)
Viral Therapy (1)
Anti-Tumor Immunity (1)
Immune infiltrate (1)
Vemurafenib (1)
First line (1)
IP-001 (1)
FOLFOX (1)
Pembrolizumab (1)
Metastatic colorectal cancer (1)
Capecitabine (1)
Immunotherapy (1)
Bevacizumab (1)
Cetuximab (1)
Oxaliplatin (1)

Previous page
1 / 232
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 232
Next page

Sort by:

Relevance

Page size

Necrocide 1 mediates necrotic cell death and immunogenic response in human cancer cells.

Not available

S-EPMC10073102 | biostudies-literature

Immunogenic cell death inducer cEmsy boosted cancer immunotherapy in lung adenocarcinoma

PRJNA1106833 | ENA

Stress-induced inflammation evoked by immunogenic cell death is blunted by the IRE1α kinase inhibitor KIRA6 through HSP60 targeting.

Not available

S-EPMC8738768 | biostudies-literature

Necrocide 1 Mediates Necrotic Cell Death and Immunogenic Response in Human Cancer Cells

PRJNA941807 | ENA

Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Not available

S-EPMC5706600 | biostudies-literature

Integration of miRNA:mRNA co-expression revealed crucial mechanisms modulated in immunogenic cancer cell death

Immunogenic cell death (ICD) in cancer represents a functionally unique therapeutic response that can induce tumor-targeting immune responses. ICD is characterized by the exposure and release of numerous damage-associated molecular patterns (DAMPs), which confer adjuvanticity to dying cancer cells. ...

ORGANISM(S): Homo sapiens

2022-08-08 | E-MTAB-11799 | biostudies-arrayexpress

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

Not available

S-EPMC4352954 | biostudies-literature

Belantamab Mafodotin Triggers Immune Invigoration in Multiple Myeloma Via Inflammatory and Immunogenic Cell Death [Xenium]

PRJNA1322471 | ENA

Viral Mimicry may Help Explain Immunogenic Cell Death

PRJNA1424912 | ENA

Immunogenic Cell Death and Immunotherapy of Multiple Myeloma.

Not available

S-EPMC6476910 | biostudies-literature